Next Generation News and Research

RSS

Intrexon Corporation, ZIOPHARM enter partnership to develop, commercialize DNA-based therapeutics

ZIOPHARM Oncology, a small molecule late-stage oncology drug development company, and Intrexon Corporation, a next generation synthetic biology company, announced today a global exclusive channel partnership in oncology where ZIOPHARM will develop and commercialize DNA-based therapeutics using Intrexon's UltraVector Technology.

7 Jan 2011

Curis announces selection of CUDC-907 as development candidate for cancer

Curis, a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the Company has selected CUDC-907, an orally available, synthetic small molecule inhibitor of phosphatidylinositol-3-kinase and histone deacetylase as a development candidate from its targeted cancer programs.

7 Jan 2011

GT Life Sciences and BGI complete CHO-K1 genome sequencing

GT Life Sciences, a privately held biotechnology company that utilizes a proven metabolic modeling and experimental platform to drive the discovery and design of new products and processes for the life sciences field, and BGI, the largest genomics organization in the world, announced that they have successfully completed for the first time the sequencing of the Chinese hamster ovary genome.

6 Jan 2011

MacroGenics commences MGAH22 Phase I trail for patients with HER2-positive cancer

MacroGenics, a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced that it had administered drug to the first cohort of patients in a Phase I clinical trial of MGAH22.

6 Jan 2011

Symphogen closes €100 million stock to a group of investors

Symphogen, a private biopharmaceutical company developing superior antibody therapeutics to treat cancer, infectious and autoimmune diseases, announced today that it closed a €100 million placement of Preferred Stock to a group of investors.

6 Jan 2011

Stereotaxis extends strategic partnership to distribute magnetic ablation catheters

Stereotaxis, Inc. announced today that the Company and its existing strategic catheter partner have extended their exclusive worldwide agreement for the distribution of existing approved magnetic ablation catheters through the end of 2015.

6 Jan 2011

Cell Biosciences introduces FluorChem M MultiFluor for detectig multicolor fluorescent Western blots

Cell Biosciences, a provider of innovative protein analysis tools to life science researchers, today announced the launch of the latest addition to their premier line of next-generation imaging products, the FluorChem M MultiFluor system.

5 Jan 2011

Carbylan completes enrollment in COR1.0 feasibility trial of Hydros and Hydros TA in knee osteoarthritis

Carbylan BioSurgery, Inc. announced today the completion of patient enrollment in their double-blinded, multi-center COR1.0 feasibility trial to evaluate the safety and effectiveness of two products - Hydros and Hydros TA Joint Therapies - in patients with osteoarthritis of the knee. Hydros and Hydros TA are next generation viscosupplement and viscosupplement/steroid combination products.

5 Jan 2011

OrbusNeich expands patent protection for Genous endothelial progenitor cell capture technology

OrbusNeich today announced that the United States Patent and Trademark Office (USPTO) has granted an additional patent expanding protection of the company's Genous endothelial progenitor cell (EPC) capture technology.

5 Jan 2011

Qualcomm's wireless Internet of Everything Module integrated into Telcare 3GM blood glucose meter

Qualcomm Incorporated and Telcare Incorporated today announced plans to integrate Qualcomm's wireless Internet of Everything Module (IEM) into the Telcare 3GM™ blood glucose meter being developed by Telcare. Telcare 3GM, currently in prototype phase, is designed to transfer blood glucose readings to a patient's family members or physician with each test.

5 Jan 2011

FDA approves Gore's C3 Delivery System to deploy EXCLUDER AAA Endoprosthesis

W. L. Gore & Associates (Gore) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to market the GORE® C3 Delivery System to deploy the GORE® EXCLUDER® AAA Endoprosthesis as a minimally invasive treatment for patients suffering from an abdominal aortic aneurysm (AAA).

5 Jan 2011

MGH, Veridex establish research center of excellence on circulating tumor cell technologies

Massachusetts General Hospital (MGH) has entered into a collaborative agreement with Veridex LLC to establish a center of excellence in research on circulating tumor cell (CTC) technologies. The overall goal of the agreement is to develop and commercialize novel technologies for capturing and characterizing CTCs, solid tumor cells found at extremely low levels in the bloodstream, which may offer a key to noninvasive characterization of cancer and potentially to early detection.

4 Jan 2011

Stryker closes acquisition of Boston Scientific Neurovascular

Stryker Corporation announced today the closing of its previously announced acquisition of the assets of the Neurovascular division of Boston Scientific, the global leader in the approximately $900 million worldwide neurovascular market, which includes products used for the minimally invasive treatment of hemorrhagic and ischemic stroke.

From Stryker 4 Jan 2011

First whole genome sequence of Parsi breast cancer woman

Avesthagen Limited has yet again established its position as a leader in the successful application of next gen technologies as it announces the completion of the first Parsi breast cancer whole genome sequence of a 74-year-old Parsi woman with a heritable form of breast cancer. The incidence of breast cancer in most populations is strongly linked to a genetic basis but little is known about the variants at the present time.

4 Jan 2011

Stryker acquires Boston Scientific's Neurovascular business

Boston Scientific Corporation today announced that it has completed the sale of its Neurovascular business to Stryker Corporation.

From Stryker 3 Jan 2011

Hydrocephalus in Ugandan children linked to farm animals, previous bacterial infection

Hydrocephalus in Ugandan children and other developing countries is seasonal, linked to farm animals and in part, caused by previous bacterial infection, according to an international team of researchers from Uganda and the United States, who believe that the best approach to this problem is prevention.

3 Jan 2011

Warburg Pincus affiliates to acquire ReSearch Pharmaceutical Services for $6.10 per share

ReSearch Pharmaceutical Services, Inc. (RPS) announced today it has entered into an agreement to sell the company to affiliates of Warburg Pincus, LLC, the global private equity firm, in an all cash transaction valued at $6.10 per share. The Board of Directors of RPS unanimously approved the acquisition agreement and recommended that RPS shareholders approve the transaction. It is presently anticipated that closing of the transaction will occur in February 2011.

28 Dec 2010

U.S judge awards $11.7 million to DF/HCC for large-scale prostrate cancer research

Dana Farber/Harvard Cancer Center will launch a new multi-million dollar grant award program focused on prostate cancer research. It will be administered in collaboration with the Prostate Cancer Foundation.

28 Dec 2010

Positron granted U.S. patents for quantum photodetectors

Positron Corporation, a leading molecular imaging company specializing in the field of nuclear cardiology, today announced it has received two U.S. patents for its proprietary quantum photodetectors.

24 Dec 2010

Paternal diet affects lipid metabolizing genes in offspring

Scientists at the University of Massachusetts Medical School and the University of Texas at Austin have uncovered evidence that environmental influences experienced by a father can be passed down to the next generation, "reprogramming" how genes function in offspring. A new study published this week in Cell shows that environmental cues-in this case, diet-influence genes in mammals from one generation to the next, evidence that until now has been sparse.

24 Dec 2010

Next Generation News and Research

Intrexon Corporation, ZIOPHARM enter partnership to develop, commercialize DNA-based therapeutics

Curis announces selection of CUDC-907 as development candidate for cancer

GT Life Sciences and BGI complete CHO-K1 genome sequencing

MacroGenics commences MGAH22 Phase I trail for patients with HER2-positive cancer

Symphogen closes €100 million stock to a group of investors

Stereotaxis extends strategic partnership to distribute magnetic ablation catheters

Cell Biosciences introduces FluorChem M MultiFluor for detectig multicolor fluorescent Western blots

Carbylan completes enrollment in COR1.0 feasibility trial of Hydros and Hydros TA in knee osteoarthritis

OrbusNeich expands patent protection for Genous endothelial progenitor cell capture technology

Qualcomm's wireless Internet of Everything Module integrated into Telcare 3GM blood glucose meter

FDA approves Gore's C3 Delivery System to deploy EXCLUDER AAA Endoprosthesis

MGH, Veridex establish research center of excellence on circulating tumor cell technologies

Stryker closes acquisition of Boston Scientific Neurovascular

First whole genome sequence of Parsi breast cancer woman

Stryker acquires Boston Scientific's Neurovascular business

Hydrocephalus in Ugandan children linked to farm animals, previous bacterial infection

Warburg Pincus affiliates to acquire ReSearch Pharmaceutical Services for $6.10 per share

U.S judge awards $11.7 million to DF/HCC for large-scale prostrate cancer research

Positron granted U.S. patents for quantum photodetectors

Paternal diet affects lipid metabolizing genes in offspring

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News